389 related articles for article (PubMed ID: 31650514)
1. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
[TBL] [Abstract][Full Text] [Related]
2. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
3. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
4. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
5. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
Cui J; Klepser DG; McAdam-Marx C
J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
[No Abstract] [Full Text] [Related]
6. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
7. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
9. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Langer J; Hunt B; Valentine WJ
J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
Adv Ther; 2017 Apr; 34(4):954-965. PubMed ID: 28281218
[TBL] [Abstract][Full Text] [Related]
13. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
Hunt B; McConnachie CC; Gamble C; Dang-Tan T
J Med Econ; 2017 Nov; 20(11):1117-1120. PubMed ID: 28651479
[TBL] [Abstract][Full Text] [Related]
15. Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
Rosenstock J; Cariou B; Eliasson J; Frappin G; Kaltoft MS; Montanya E; Knop FK
Diabetes Obes Metab; 2024 Feb; 26(2):532-539. PubMed ID: 37935463
[TBL] [Abstract][Full Text] [Related]
16. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
[TBL] [Abstract][Full Text] [Related]
19. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
20. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Vidal J; Malkin SJP; Hunt B; Martín V; Hallén N; Javier Ortega F
Diabetes Ther; 2020 Feb; 11(2):509-521. PubMed ID: 31925724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]